Detalhe da pesquisa
1.
Time interval between diagnosis to treatment of breast cancer and the impact of health insurance coverage: a sub analysis of the AMAZONA III Study (GBECAM 0115).
Breast Cancer Res Treat
; 198(1): 123-130, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36586038
2.
Breast Cancer Treatment Delay in SafetyNet Health Systems, Houston Versus Southeast Brazil.
Oncologist
; 27(5): 344-351, 2022 05 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35348756
3.
Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer.
Br J Cancer
; 125(1): 38-47, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33828257
4.
Does the Sequence of Anthracycline and Taxane Matter? The NeoSAMBA Trial.
Oncologist
; 25(9): 758-764, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32476183
5.
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
N Engl J Med
; 377(2): 122-131, 2017 Jul 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-28581356
6.
The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115).
Breast Cancer Res Treat
; 183(3): 749-757, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32728860
7.
Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer.
Anticancer Drugs
; 30(8): 866-872, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31305270
8.
Implications of ESR1 Mutations in Hormone Receptor-Positive Breast Cancer.
Curr Treat Options Oncol
; 19(5): 24, 2018 04 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-29666928
9.
Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 15(12): 1351-60, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25273343
10.
Baby steps: Pregnancy outcomes after human epidermal growth factor receptor 2-targeted therapy.
Cancer
; 125(2): 181-184, 2019 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30500982
11.
Real-World Evidence of Ribociclib Plus Aromatase Inhibitors as First-Line Treatment in Advanced Breast Cancer: The BrasiLEEira Study.
JCO Glob Oncol
; 10: e2300484, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38603658
12.
Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience.
Oncologist
; 18(2): 134-40, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23359433
13.
Nuclear and Cytoplasmic hTERT, Tumor-Infiltrating Lymphocytes, and Telomere Elongation Leukocytes Are Independent Factors in the Response to Neoadjuvant Treatment in HER2-Enriched Breast Cancer.
Curr Oncol
; 30(4): 4094-4109, 2023 04 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37185424
14.
Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine.
Clin Cancer Res
; 29(2): 389-400, 2023 01 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36346687
15.
Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study.
Breast Cancer Res Treat
; 133(1): 237-46, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22286314
16.
Is there a window of opportunity to optimize trastuzumab cardiac monitoring?
World J Cardiol
; 14(7): 403-410, 2022 Jul 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36161060
17.
Timelines to initiate a phase III trial across the globe: a sub-analysis of the APHINITY trial.
Ecancermedicalscience
; 16: 1379, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35702414
18.
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial.
Eur J Cancer
; 166: 219-228, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35313167
19.
Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy.
J Natl Cancer Inst
; 114(8): 1117-1126, 2022 08 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35512402
20.
Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study.
Ther Adv Med Oncol
; 14: 17588359221141760, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36601632